Newscenter - Press Releases banner
Sensing is Life
Our vision is to create the uncontested leader in optical solutions through bold investments in disruptive innovation and
continuous transformation delivering best-in-class profitability and growth.
Navigation Menu
Asset Publisher

AS7341L Spectral Sensor

BiologyWorks chooses ams OSRAM spectral sensors for industry-changing device that provides COVID-19 testing and much more

2021/07/08

New BiologyWorks k(now)™ device redefines healthcare testing by providing highly accurate testing for COVID-19 or other molecular assays.

News Facts:

  • New BiologyWorks k(now)™ device redefines healthcare testing by providing highly accurate testing for COVID-19 or other molecular assays.
  • Multi-spectral sensors from ams OSRAM enable molecular testing for the virus by analyzing nasal samples.  
  • The flexible spectral sensors are standardized for all light wavelengths, allowing Biology-Works™ to use different assays to identify everything from COVID-19 to Influenza A/B to glucose levels and STDs.

Premstaetten, Austria (8th July 2021) -- ams OSRAM (SIX: AMS), a global leader in optical solutions, today announced its multi-spectral technology is a key component of the Biolo-gyWorks (k)now device, a rapid, lab-quality and affordable molecular test for COVID-19 (SARS-CoV-2) and other infections.

“The ams OSRAM spectral sensor is a critical component of the BiologyWorks k(now) device because of its unique ability to quickly and reliably identify samples further ensuring the delivery of accurate, digital results,” noted Peter Marx, a BiologyWorks founder. 

Using the BiologyWorks k(now) device is simple. Samples are collected with an anterior nasal swab, consecutively added to two test tubes with fluids, mixed and then a drop of the mixture is added to a disposable cartridge. The cartridge is then inserted into the device for molecular testing that is highly accurate, inexpensive and examines multiple indicators at once. COVID-19 results can be found by scanning a QR code on the device display with a smartphone. 

The BiologyWorks k(now) device features the AS7341L, a 10-channel spectral sensor that offers highly accurate spectral identification for reflection or fluorescence measurements. The multi-wavelength approach of the AS7341L enables cost-effective multi-analyte detection and is available in a mobile device-compatible package. BiologyWorks’ cutting-edge software and hardware, combined with LAMP chemistry, completes the analysis, delivering results in minutes at home. 

“We are proud to be at the forefront of spectral sensing technology, which enables point-of-care and in-home COVID-19 testing by products such as the BiologyWorks k(now) device,” said Jennifer Zhao, Executive Vice President of the Advanced Optical Sensors business unit at ams OSRAM. “Our sensor solutions are designed to improve speed, sensitivity and cycle time for a wide variety of diagnostic testing. These kinds of rapid, accurate and cost-effective mass-testing solutions can make a huge difference in controlling the virus and help us support the restarting of the economy and resume many of the social activities we have missed over the past year.” 

For more technical information, to enquire about the evaluation kit, or for sample requests, go to AS7341L.

For further information 
Media Relations 
Sarah Carlson 
Sr. Manager of Marketing Communications, North America
T: +1 248 755-7680
sarah.carlson@osram-os.com
ams-osram.com

Amy Flécher
Vice President Corporate Communications and Marketing
T: +43 664 8816 2121
press@ams.com
ams-osram.com

 

About ams OSRAM Group

The ams OSRAM Group, including the listed companies ams AG as parent company and OSRAM Licht AG is a global leader in optical solutions. By adding intelligence to light and passion to innovation, we enrich people’s lives. This is what we mean by Sensing is Life. With over 110 years of combined history, our core is defined by imagination, deep engineering expertise and the ability to provide global industrial capacity in sensor and light technologies. We create exciting innovations that enable our customers in the consumer, automotive, healthcare and industrial sectors maintain their competitive edge and drive innovation that meaningfully improves the quality of life in terms of health, safety and convenience, while reducing impact on the environment. Our around 30,000 employees worldwide focus on innovation across sensing, illumination and visualization to make journeys safer, medical diagnosis more accurate and daily moments in communication a richer experience. Our work creates technology for breakthrough applications, which is reflected in over 15,000 patents granted and applied. Headquartered in Premstaetten/Graz (Austria) with a co-headquarters in Munich (Germany), the group achieved well over USD 5 billion combined revenues in 2020 (pro-forma). ams AG is a listed company on the SIX Swiss Exchange (SIX: AMS/ISIN: AT0000A18XM4). OSRAM Licht AG remains a listed company on the XETRA market in Germany (XETRA: OSR/ISIN: DE000LED4000).

Find out more about us on our website.

ams is a registered trademark of ams AG. In addition many of our products and services are registered or filed trademarks of ams Group. All other company or product names mentioned herein may be trademarks or registered trademarks of their respective owners. Information provided in this press release is accurate at time of publication and is subject to change without advance notice.

Join ams OSRAM Social Media Channels:  >Twitter >LinkedIn >Facebook >Youtube

 

About BiologyWorks

BiologyWorks is the creator of BiologyWorks k(now), a rapid molecular test with high accuracy, even in those asymptomatic. It offers the same certainty of results as PCR laboratory tests, which are considered to offer the highest accuracy. The patented molecular testing technology can be adapted to test for any number of different genetic biomarkers with a long-term vision of providing a multitude of testing solutions across different areas of human health. The company prioritizes the consumerization of medicine and putting healthcare back in the hands of patients by empowering them to learn more about their bodies and health. For further information, please visit the BiologyWorks website.